APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Immuno-oncology Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Immuno-oncology Drugs Market Outlook and Growth Opportunities 2026

Report ID 174002040422 December 2025218 pages

Choose your research edition.

Industry ResearchImmuno-oncology Drugs Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Immuno-oncology Drugs Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Immuno-oncology Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immuno-oncology Drugs Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Immuno-oncology Drugs Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Immuno-oncology Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Immuno-oncology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Immuno-oncology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Immuno-oncology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Immuno-oncology Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Immuno-oncology Drugs market include Sanofi S.A., Johnson & Johnson, Merck & Co., Lonza Group, Eli Lilly and Company, Pfizer Inc., Ferring Pharmaceuticals, Amgen, Inc and AbbVie, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Immuno-oncology Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Immuno-oncology Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Immuno-oncology Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Immuno-oncology Drugs market.

Immuno-oncology Drugs Segment by Company

Sanofi S.A.

Johnson & Johnson

Merck & Co.

Lonza Group

Eli Lilly and Company

Pfizer Inc.

Ferring Pharmaceuticals

Amgen, Inc

AbbVie, Inc.

AstraZeneca, Plc

Spring Bank Pharmaceuticals, Inc.

Prometheus Therapeutics & Diagnostics

Novartis International AG

Incyte

ImmunoCellular Therapeutics

Hoffmann-La Roche AG

Gilead Sciences Inc.

Galena Biopharma

Enzo Biochem, Inc.

EMD Serono, Inc.

Dendreon Corporation

Celldex Therapeutics

Celgene Corporation

Bristol-Myers Squibb

Bio-Rad Laboratories, Inc.

Bavarian Nordic

Avantor, Inc.

Agilent Technologies Inc.

Agenus Inc.

Aduro BioTech

Immuno-oncology Drugs Segment by Type

Oncolytic Virus

Immune System Modulators

Immune Checkpoint Inhibitors

Cancer Vaccines

Others

Immuno-oncology Drugs Segment by Application

Clinics

Hospitals

Community Centers

Immuno-oncology Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Immuno-oncology Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Immuno-oncology Drugs key companies, revenue, market share, and recent developments.

3. To split the Immuno-oncology Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Immuno-oncology Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Immuno-oncology Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Immuno-oncology Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immuno-oncology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immuno-oncology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immuno-oncology Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Immuno-oncology Drugs industry.

Chapter 3: Detailed analysis of Immuno-oncology Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Immuno-oncology Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Immuno-oncology Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Immuno-oncology Drugs Industry Trends Table 2. Immuno-oncology Drugs Industry Drivers Table 3. Immuno-oncology Drugs Industry Opportunities and Challenges Table 4. Immuno-oncology Drugs Industry Restraints Table 5. Global Immuno-oncology Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Immuno-oncology Drugs Revenue Share by Company (2021-2026) Table 7. Global Immuno-oncology Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Immuno-oncology Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Immuno-oncology Drugs Company, Product Type & Application Table 10. Global Immuno-oncology Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Immuno-oncology Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oncolytic Virus Table 15. Significant Companies of Immune System Modulators Table 16. Significant Companies of Immune Checkpoint Inhibitors Table 17. Significant Companies of Cancer Vaccines Table 18. Significant Companies of Others Table 19. Global Immuno-oncology Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Immuno-oncology Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Immuno-oncology Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Immuno-oncology Drugs Sales Value Share by Type (2021-2026) Table 23. Global Immuno-oncology Drugs Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Clinics Table 25. Significant Companies of Hospitals Table 26. Significant Companies of Community Centers Table 27. Global Immuno-oncology Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Immuno-oncology Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Immuno-oncology Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Immuno-oncology Drugs Sales Value Share by Application (2021-2026) Table 31. Global Immuno-oncology Drugs Sales Value Share by Application (2027-2032) Table 32. Global Immuno-oncology Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Immuno-oncology Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Immuno-oncology Drugs Sales Value Share by Region (2021-2026) Table 35. Global Immuno-oncology Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Immuno-oncology Drugs Sales Value Share by Region (2027-2032) Table 37. Global Immuno-oncology Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Immuno-oncology Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Immuno-oncology Drugs Sales Value Market Share by Country (2021-2026) Table 40. Global Immuno-oncology Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Immuno-oncology Drugs Sales Value Market Share by Country (2027-2032) Table 42. Sanofi S.A. Company Information Table 43. Sanofi S.A. Business Overview Table 44. Sanofi S.A. Immuno-oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Sanofi S.A. Immuno-oncology Drugs Product Portfolio Table 46. Sanofi S.A. Recent Development Table 47. Johnson & Johnson Company Information Table 48. Johnson & Johnson Business Overview Table 49. Johnson & Johnson Immuno-oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Johnson & Johnson Immuno-oncology Drugs Product Portfolio Table 51. Johnson & Johnson Recent Development Table 52. Merck & Co. Company Information Table 53. Merck & Co. Business Overview Table 54. Merck & Co. Immuno-oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Merck & Co. Immuno-oncology Drugs Product Portfolio Table 56. Merck & Co. Recent Development Table 57. Lonza Group Company Information Table 58. Lonza Group Business Overview Table 59. Lonza Group Immuno-oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Lonza Group Immuno-oncology Drugs Product Portfolio Table 61. Lonza Group Recent Development Table 62. Eli Lilly and Company Company Information Table 63. Eli Lilly and Company Business Overview Table 64. Eli Lilly and Company Immuno-oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Eli Lilly and Company Immuno-oncology Drugs Product Portfolio Table 66. Eli Lilly and Company Recent Development Table 67. Pfizer Inc. Company Information Table 68. Pfizer Inc. Business Overview Table 69. Pfizer Inc. Immuno-oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Pfizer Inc. Immuno-oncology Drugs Product Portfolio Table 71. Pfizer Inc. Recent Development Table 72. Ferring Pharmaceuticals Company Information Table 73. Ferring Pharmaceuticals Business Overview Table 74. Ferring Pharmaceuticals Immuno-oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Ferring Pharmaceuticals Immuno-oncology Drugs Product Portfolio Table 76. Ferring Pharmaceuticals Recent Development Table 77. Amgen, Inc Company Information Table 78. Amgen, Inc Business Overview Table 79. Amgen, Inc Immuno-oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Amgen, Inc Immuno-oncology Drugs Product Portfolio Table 81. Amgen, Inc Recent Development Table 82. AbbVie, Inc. Company Information Table 83. AbbVie, Inc. Business Overview Table 84. AbbVie, Inc. Immuno-oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. AbbVie, Inc. Immuno-oncology Drugs Product Portfolio Table 86. AbbVie, Inc. Recent Development Table 87. AstraZeneca, Plc Company Information Table 88. AstraZeneca, Plc Business Overview Table 89. AstraZeneca, Plc Immuno-oncology Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. AstraZeneca, Plc Immuno-oncology Drugs Product Portfolio Table 91. AstraZeneca, Plc Recent Development Table 92. Spring Bank Pharmaceuticals, Inc. Company Information Table 93. Spring Bank Pharmaceuticals, Inc. Business Overview Table 94. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product Portfolio Table 96. Spring Bank Pharmaceuticals, Inc. Recent Development Table 97. Prometheus Therapeutics & Diagnostics Company Information Table 98. Prometheus Therapeutics & Diagnostics Business Overview Table 99. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Portfolio Table 101. Prometheus Therapeutics & Diagnostics Recent Development Table 102. Novartis International AG Company Information Table 103. Novartis International AG Business Overview Table 104. Novartis International AG Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Novartis International AG Immuno-oncology Drugs Product Portfolio Table 106. Novartis International AG Recent Development Table 107. Incyte Company Information Table 108. Incyte Business Overview Table 109. Incyte Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Incyte Immuno-oncology Drugs Product Portfolio Table 111. Incyte Recent Development Table 112. ImmunoCellular Therapeutics Company Information Table 113. ImmunoCellular Therapeutics Business Overview Table 114. ImmunoCellular Therapeutics Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. ImmunoCellular Therapeutics Immuno-oncology Drugs Product Portfolio Table 116. ImmunoCellular Therapeutics Recent Development Table 117. Hoffmann-La Roche AG Company Information Table 118. Hoffmann-La Roche AG Business Overview Table 119. Hoffmann-La Roche AG Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. Hoffmann-La Roche AG Immuno-oncology Drugs Product Portfolio Table 121. Hoffmann-La Roche AG Recent Development Table 122. Gilead Sciences Inc. Company Information Table 123. Gilead Sciences Inc. Business Overview Table 124. Gilead Sciences Inc. Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. Gilead Sciences Inc. Immuno-oncology Drugs Product Portfolio Table 126. Gilead Sciences Inc. Recent Development Table 127. Galena Biopharma Company Information Table 128. Galena Biopharma Business Overview Table 129. Galena Biopharma Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 130. Galena Biopharma Immuno-oncology Drugs Product Portfolio Table 131. Galena Biopharma Recent Development Table 132. Enzo Biochem, Inc. Company Information Table 133. Enzo Biochem, Inc. Business Overview Table 134. Enzo Biochem, Inc. Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 135. Enzo Biochem, Inc. Immuno-oncology Drugs Product Portfolio Table 136. Enzo Biochem, Inc. Recent Development Table 137. EMD Serono, Inc. Company Information Table 138. EMD Serono, Inc. Business Overview Table 139. EMD Serono, Inc. Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 140. EMD Serono, Inc. Immuno-oncology Drugs Product Portfolio Table 141. EMD Serono, Inc. Recent Development Table 142. Dendreon Corporation Company Information Table 143. Dendreon Corporation Business Overview Table 144. Dendreon Corporation Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 145. Dendreon Corporation Immuno-oncology Drugs Product Portfolio Table 146. Dendreon Corporation Recent Development Table 147. Celldex Therapeutics Company Information Table 148. Celldex Therapeutics Business Overview Table 149. Celldex Therapeutics Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 150. Celldex Therapeutics Immuno-oncology Drugs Product Portfolio Table 151. Celldex Therapeutics Recent Development Table 152. Celgene Corporation Company Information Table 153. Celgene Corporation Business Overview Table 154. Celgene Corporation Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 155. Celgene Corporation Immuno-oncology Drugs Product Portfolio Table 156. Celgene Corporation Recent Development Table 157. Bristol-Myers Squibb Company Information Table 158. Bristol-Myers Squibb Business Overview Table 159. Bristol-Myers Squibb Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 160. Bristol-Myers Squibb Immuno-oncology Drugs Product Portfolio Table 161. Bristol-Myers Squibb Recent Development Table 162. Bio-Rad Laboratories, Inc. Company Information Table 163. Bio-Rad Laboratories, Inc. Business Overview Table 164. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 165. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product Portfolio Table 166. Bio-Rad Laboratories, Inc. Recent Development Table 167. Bavarian Nordic Company Information Table 168. Bavarian Nordic Business Overview Table 169. Bavarian Nordic Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 170. Bavarian Nordic Immuno-oncology Drugs Product Portfolio Table 171. Bavarian Nordic Recent Development Table 172. Avantor, Inc. Company Information Table 173. Avantor, Inc. Business Overview Table 174. Avantor, Inc. Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 175. Avantor, Inc. Immuno-oncology Drugs Product Portfolio Table 176. Avantor, Inc. Recent Development Table 177. Agilent Technologies Inc. Company Information Table 178. Agilent Technologies Inc. Business Overview Table 179. Agilent Technologies Inc. Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 180. Agilent Technologies Inc. Immuno-oncology Drugs Product Portfolio Table 181. Agilent Technologies Inc. Recent Development Table 182. Agenus Inc. Company Information Table 183. Agenus Inc. Business Overview Table 184. Agenus Inc. Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 185. Agenus Inc. Immuno-oncology Drugs Product Portfolio Table 186. Agenus Inc. Recent Development Table 187. Aduro BioTech Company Information Table 188. Aduro BioTech Business Overview Table 189. Aduro BioTech Immuno-oncology Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 190. Aduro BioTech Immuno-oncology Drugs Product Portfolio Table 191. Aduro BioTech Recent Development Table 192. Research Programs/Design for This Report Table 193. Authors List of This Report Table 194. Secondary Sources Table 195. Primary Sources List of Figures Figure 1. Immuno-oncology Drugs Product Image Figure 2. Global Immuno-oncology Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Immuno-oncology Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oncolytic Virus Image Figure 8. Immune System Modulators Image Figure 9. Immune Checkpoint Inhibitors Image Figure 10. Cancer Vaccines Image Figure 11. Others Image Figure 12. Global Immuno-oncology Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Immuno-oncology Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Immuno-oncology Drugs Sales Value Share by Type (2021-2032) Figure 15. Clinics Image Figure 16. Hospitals Image Figure 17. Community Centers Image Figure 18. Global Immuno-oncology Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Immuno-oncology Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Immuno-oncology Drugs Sales Value Share by Application (2021-2032) Figure 21. Global Immuno-oncology Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Immuno-oncology Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Immuno-oncology Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. North America Immuno-oncology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Immuno-oncology Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Immuno-oncology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Immuno-oncology Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Immuno-oncology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Immuno-oncology Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. South America Immuno-oncology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Immuno-oncology Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Immuno-oncology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Immuno-oncology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Oncolytic Virus
  • Immune System Modulators
  • Immune Checkpoint Inhibitors
  • Cancer Vaccines
  • Others
Applications
  • Clinics
  • Hospitals
  • Community Centers
Companies covered
  • Sanofi S.A.
  • Johnson & Johnson
  • Merck & Co.
  • Lonza Group
  • Eli Lilly and Company
  • Pfizer Inc.
  • Ferring Pharmaceuticals
  • Amgen, Inc
  • AbbVie, Inc.
  • AstraZeneca, Plc
  • Spring Bank Pharmaceuticals, Inc.
  • Prometheus Therapeutics & Diagnostics
  • Novartis International AG
  • Incyte
  • ImmunoCellular Therapeutics
  • Hoffmann-La Roche AG
  • Gilead Sciences Inc.
  • Galena Biopharma
  • Enzo Biochem, Inc.
  • EMD Serono, Inc.
  • Dendreon Corporation
  • Celldex Therapeutics
  • Celgene Corporation
  • Bristol-Myers Squibb
  • Bio-Rad Laboratories, Inc.
  • Bavarian Nordic
  • Avantor, Inc.
  • Agilent Technologies Inc.
  • Agenus Inc.
  • Aduro BioTech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Immuno-oncology Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Immuno-oncology Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Immuno-oncology Drugs Market Dynamics
  1. 2.1 Immuno-oncology Drugs Industry Trends
  2. 2.2 Immuno-oncology Drugs Industry Drivers
  3. 2.3 Immuno-oncology Drugs Industry Opportunities and Challenges
  4. 2.4 Immuno-oncology Drugs Industry Restraints
3 Immuno-oncology Drugs Market by Company
  1. 3.1 Global Immuno-oncology Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Immuno-oncology Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Immuno-oncology Drugs Company Ranking (2024-2026)
  4. 3.4 Global Immuno-oncology Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Immuno-oncology Drugs Company Product Type and Application
  6. 3.6 Global Immuno-oncology Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Immuno-oncology Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Immuno-oncology Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Immuno-oncology Drugs Market by Type
  1. 4.1 Immuno-oncology Drugs Type Introduction
  2. 4.1.1 Oncolytic Virus
  3. 4.1.2 Immune System Modulators
  4. 4.1.3 Immune Checkpoint Inhibitors
  5. 4.1.4 Cancer Vaccines
  6. 4.1.5 Others
  7. 4.2 Global Immuno-oncology Drugs Sales Value by Type
  8. 4.2.1 Global Immuno-oncology Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Immuno-oncology Drugs Sales Value by Type (2021-2032)
  10. 4.2.3 Global Immuno-oncology Drugs Sales Value Share by Type (2021-2032)
5 Immuno-oncology Drugs Market by Application
  1. 5.1 Immuno-oncology Drugs Application Introduction
  2. 5.1.1 Clinics
  3. 5.1.2 Hospitals
  4. 5.1.3 Community Centers
  5. 5.2 Global Immuno-oncology Drugs Sales Value by Application
  6. 5.2.1 Global Immuno-oncology Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Immuno-oncology Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Immuno-oncology Drugs Sales Value Share by Application (2021-2032)
6 Immuno-oncology Drugs Regional Value Analysis
  1. 6.1 Global Immuno-oncology Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Immuno-oncology Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Immuno-oncology Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Immuno-oncology Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Immuno-oncology Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Immuno-oncology Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Immuno-oncology Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Immuno-oncology Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Immuno-oncology Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Immuno-oncology Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Immuno-oncology Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Immuno-oncology Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Immuno-oncology Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Immuno-oncology Drugs Sales Value Share by Country, 2025 VS 2032
7 Immuno-oncology Drugs Country-level Value Analysis
  1. 7.1 Global Immuno-oncology Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Immuno-oncology Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Immuno-oncology Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Immuno-oncology Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Immuno-oncology Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Immuno-oncology Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Immuno-oncology Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi S.A.
  2. 8.1.1 Sanofi S.A. Company Information
  3. 8.1.2 Sanofi S.A. Business Overview
  4. 8.1.3 Sanofi S.A. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi S.A. Immuno-oncology Drugs Product Portfolio
  6. 8.1.5 Sanofi S.A. Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Immuno-oncology Drugs Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Merck & Co.
  14. 8.3.1 Merck & Co. Company Information
  15. 8.3.2 Merck & Co. Business Overview
  16. 8.3.3 Merck & Co. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co. Immuno-oncology Drugs Product Portfolio
  18. 8.3.5 Merck & Co. Recent Developments
  19. 8.4 Lonza Group
  20. 8.4.1 Lonza Group Company Information
  21. 8.4.2 Lonza Group Business Overview
  22. 8.4.3 Lonza Group Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Lonza Group Immuno-oncology Drugs Product Portfolio
  24. 8.4.5 Lonza Group Recent Developments
  25. 8.5 Eli Lilly and Company
  26. 8.5.1 Eli Lilly and Company Company Information
  27. 8.5.2 Eli Lilly and Company Business Overview
  28. 8.5.3 Eli Lilly and Company Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly and Company Immuno-oncology Drugs Product Portfolio
  30. 8.5.5 Eli Lilly and Company Recent Developments
  31. 8.6 Pfizer Inc.
  32. 8.6.1 Pfizer Inc. Company Information
  33. 8.6.2 Pfizer Inc. Business Overview
  34. 8.6.3 Pfizer Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Inc. Immuno-oncology Drugs Product Portfolio
  36. 8.6.5 Pfizer Inc. Recent Developments
  37. 8.7 Ferring Pharmaceuticals
  38. 8.7.1 Ferring Pharmaceuticals Company Information
  39. 8.7.2 Ferring Pharmaceuticals Business Overview
  40. 8.7.3 Ferring Pharmaceuticals Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Ferring Pharmaceuticals Immuno-oncology Drugs Product Portfolio
  42. 8.7.5 Ferring Pharmaceuticals Recent Developments
  43. 8.8 Amgen, Inc
  44. 8.8.1 Amgen, Inc Company Information
  45. 8.8.2 Amgen, Inc Business Overview
  46. 8.8.3 Amgen, Inc Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Amgen, Inc Immuno-oncology Drugs Product Portfolio
  48. 8.8.5 Amgen, Inc Recent Developments
  49. 8.9 AbbVie, Inc.
  50. 8.9.1 AbbVie, Inc. Company Information
  51. 8.9.2 AbbVie, Inc. Business Overview
  52. 8.9.3 AbbVie, Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AbbVie, Inc. Immuno-oncology Drugs Product Portfolio
  54. 8.9.5 AbbVie, Inc. Recent Developments
  55. 8.10 AstraZeneca, Plc
  56. 8.10.1 AstraZeneca, Plc Company Information
  57. 8.10.2 AstraZeneca, Plc Business Overview
  58. 8.10.3 AstraZeneca, Plc Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca, Plc Immuno-oncology Drugs Product Portfolio
  60. 8.10.5 AstraZeneca, Plc Recent Developments
  61. 8.11 Spring Bank Pharmaceuticals, Inc.
  62. 8.11.1 Spring Bank Pharmaceuticals, Inc. Company Information
  63. 8.11.2 Spring Bank Pharmaceuticals, Inc. Business Overview
  64. 8.11.3 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product Portfolio
  66. 8.11.5 Spring Bank Pharmaceuticals, Inc. Recent Developments
  67. 8.12 Prometheus Therapeutics & Diagnostics
  68. 8.12.1 Prometheus Therapeutics & Diagnostics Company Information
  69. 8.12.2 Prometheus Therapeutics & Diagnostics Business Overview
  70. 8.12.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Portfolio
  72. 8.12.5 Prometheus Therapeutics & Diagnostics Recent Developments
  73. 8.13 Novartis International AG
  74. 8.13.1 Novartis International AG Company Information
  75. 8.13.2 Novartis International AG Business Overview
  76. 8.13.3 Novartis International AG Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Novartis International AG Immuno-oncology Drugs Product Portfolio
  78. 8.13.5 Novartis International AG Recent Developments
  79. 8.14 Incyte
  80. 8.14.1 Incyte Company Information
  81. 8.14.2 Incyte Business Overview
  82. 8.14.3 Incyte Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Incyte Immuno-oncology Drugs Product Portfolio
  84. 8.14.5 Incyte Recent Developments
  85. 8.15 ImmunoCellular Therapeutics
  86. 8.15.1 ImmunoCellular Therapeutics Company Information
  87. 8.15.2 ImmunoCellular Therapeutics Business Overview
  88. 8.15.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 ImmunoCellular Therapeutics Immuno-oncology Drugs Product Portfolio
  90. 8.15.5 ImmunoCellular Therapeutics Recent Developments
  91. 8.16 Hoffmann-La Roche AG
  92. 8.16.1 Hoffmann-La Roche AG Company Information
  93. 8.16.2 Hoffmann-La Roche AG Business Overview
  94. 8.16.3 Hoffmann-La Roche AG Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Hoffmann-La Roche AG Immuno-oncology Drugs Product Portfolio
  96. 8.16.5 Hoffmann-La Roche AG Recent Developments
  97. 8.17 Gilead Sciences Inc.
  98. 8.17.1 Gilead Sciences Inc. Company Information
  99. 8.17.2 Gilead Sciences Inc. Business Overview
  100. 8.17.3 Gilead Sciences Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Gilead Sciences Inc. Immuno-oncology Drugs Product Portfolio
  102. 8.17.5 Gilead Sciences Inc. Recent Developments
  103. 8.18 Galena Biopharma
  104. 8.18.1 Galena Biopharma Company Information
  105. 8.18.2 Galena Biopharma Business Overview
  106. 8.18.3 Galena Biopharma Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Galena Biopharma Immuno-oncology Drugs Product Portfolio
  108. 8.18.5 Galena Biopharma Recent Developments
  109. 8.19 Enzo Biochem, Inc.
  110. 8.19.1 Enzo Biochem, Inc. Company Information
  111. 8.19.2 Enzo Biochem, Inc. Business Overview
  112. 8.19.3 Enzo Biochem, Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Enzo Biochem, Inc. Immuno-oncology Drugs Product Portfolio
  114. 8.19.5 Enzo Biochem, Inc. Recent Developments
  115. 8.20 EMD Serono, Inc.
  116. 8.20.1 EMD Serono, Inc. Company Information
  117. 8.20.2 EMD Serono, Inc. Business Overview
  118. 8.20.3 EMD Serono, Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  119. 8.20.4 EMD Serono, Inc. Immuno-oncology Drugs Product Portfolio
  120. 8.20.5 EMD Serono, Inc. Recent Developments
  121. 8.21 Dendreon Corporation
  122. 8.21.1 Dendreon Corporation Company Information
  123. 8.21.2 Dendreon Corporation Business Overview
  124. 8.21.3 Dendreon Corporation Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Dendreon Corporation Immuno-oncology Drugs Product Portfolio
  126. 8.21.5 Dendreon Corporation Recent Developments
  127. 8.22 Celldex Therapeutics
  128. 8.22.1 Celldex Therapeutics Company Information
  129. 8.22.2 Celldex Therapeutics Business Overview
  130. 8.22.3 Celldex Therapeutics Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Celldex Therapeutics Immuno-oncology Drugs Product Portfolio
  132. 8.22.5 Celldex Therapeutics Recent Developments
  133. 8.23 Celgene Corporation
  134. 8.23.1 Celgene Corporation Company Information
  135. 8.23.2 Celgene Corporation Business Overview
  136. 8.23.3 Celgene Corporation Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Celgene Corporation Immuno-oncology Drugs Product Portfolio
  138. 8.23.5 Celgene Corporation Recent Developments
  139. 8.24 Bristol-Myers Squibb
  140. 8.24.1 Bristol-Myers Squibb Company Information
  141. 8.24.2 Bristol-Myers Squibb Business Overview
  142. 8.24.3 Bristol-Myers Squibb Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Bristol-Myers Squibb Immuno-oncology Drugs Product Portfolio
  144. 8.24.5 Bristol-Myers Squibb Recent Developments
  145. 8.25 Bio-Rad Laboratories, Inc.
  146. 8.25.1 Bio-Rad Laboratories, Inc. Company Information
  147. 8.25.2 Bio-Rad Laboratories, Inc. Business Overview
  148. 8.25.3 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product Portfolio
  150. 8.25.5 Bio-Rad Laboratories, Inc. Recent Developments
  151. 8.26 Bavarian Nordic
  152. 8.26.1 Bavarian Nordic Company Information
  153. 8.26.2 Bavarian Nordic Business Overview
  154. 8.26.3 Bavarian Nordic Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Bavarian Nordic Immuno-oncology Drugs Product Portfolio
  156. 8.26.5 Bavarian Nordic Recent Developments
  157. 8.27 Avantor, Inc.
  158. 8.27.1 Avantor, Inc. Company Information
  159. 8.27.2 Avantor, Inc. Business Overview
  160. 8.27.3 Avantor, Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  161. 8.27.4 Avantor, Inc. Immuno-oncology Drugs Product Portfolio
  162. 8.27.5 Avantor, Inc. Recent Developments
  163. 8.28 Agilent Technologies Inc.
  164. 8.28.1 Agilent Technologies Inc. Company Information
  165. 8.28.2 Agilent Technologies Inc. Business Overview
  166. 8.28.3 Agilent Technologies Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  167. 8.28.4 Agilent Technologies Inc. Immuno-oncology Drugs Product Portfolio
  168. 8.28.5 Agilent Technologies Inc. Recent Developments
  169. 8.29 Agenus Inc.
  170. 8.29.1 Agenus Inc. Company Information
  171. 8.29.2 Agenus Inc. Business Overview
  172. 8.29.3 Agenus Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  173. 8.29.4 Agenus Inc. Immuno-oncology Drugs Product Portfolio
  174. 8.29.5 Agenus Inc. Recent Developments
  175. 8.30 Aduro BioTech
  176. 8.30.1 Aduro BioTech Company Information
  177. 8.30.2 Aduro BioTech Business Overview
  178. 8.30.3 Aduro BioTech Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  179. 8.30.4 Aduro BioTech Immuno-oncology Drugs Product Portfolio
  180. 8.30.5 Aduro BioTech Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst